Peter J. Webb

<i>In Vitro</i> and <i>In Vivo</i> Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus

Karen Joy Shaw, Wiley A. Schell, Jonathan A. Covel et al. · Antimicrobial Agents and Chemotherapy · 2018 · 113 citations · Full text

3-(1<i>H</i>-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice

Graeme Semple, Philip J. Skinner, Tawfik Gharbaoui et al. · Journal of Medicinal Chemistry · 2008 · 93 citations · Full text

No Vasodilatory Activity, Hyperlipidemia, Pharmacotherapy +21

Studies on the immunobiology of rnu/rnu “nude” rats with congenital aplasia of the thymus

Colin G. Brooks, Peter J. Webb, R. A. Robins et al. · European Journal of Immunology · 1980 · 84 citations

Laboratory Immunology, Lymphocyte Development, Staphylococcus Aureus Bacteria +16

1-Alkyl-benzotriazole-5-carboxylic Acids Are Highly Selective Agonists of the Human Orphan G-Protein-Coupled Receptor GPR109b

Graeme Semple, Philip J. Skinner, Martin C. Cherrier et al. · Journal of Medicinal Chemistry · 2006 · 79 citations · Full text

Drug Target, Pharmacotherapy, Hdl-raising Drug Niacin +16

(1a<i>R</i>,5a<i>R</i>)1a,3,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[<i>a</i>]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans

P. Douglas Boatman, Brett Lauring, Thomas O. Schrader et al. · Journal of Medicinal Chemistry · 2012 · 50 citations · Full text

Pharmacotherapy, Pharmaceutical Chemistry, Molecular Pharmacology +17